Abstract | Interferon-α (IFNα) and IFNβ, collectively known as type I IFNs, are the major effector cytokines of the host immune response against viral infections. However, the production of type I IFNs is also induced in response to bacterial ligands of innate immune receptors and/or bacterial infections, indicating a broader physiological role for these cytokines in host defence and homeostasis than was originally assumed. The main focus of this Review is the underappreciated immunomodulatory functions of type I IFNs in health and disease. We discuss their function in the regulation of innate and adaptive immune responses, the response to bacterial ligands, inflammasome activation, intestinal homeostasis and inflammatory and autoimmune diseases.
The inhibitory effect that one viral infection often exerts on the infectivity of a different virus was first observed in 1804 by Edward Jenner, who reported that herpetic infections could prevent the development of vaccinia lesions 1 . In retrospect, this observation might be the first documented description of what was later coined as the viral interference phenomenon. This phenomenon was first described in detail for plant viruses in the early 1930s 2 . After that, similar observations were made with bacteriophages 3 and with animal viruses 4 . In 1954, Nagano and Kojima reported the inhibition of viral growth in areas of rabbit skin that had been previously inoculated with ultraviolet-inactivated vaccinia virus, and in 1957, during a study of the interference produced by heat-inactivated influenza virus, Isaacs and Lindenmann identified that a secreted factor was responsible for this phenomenon and they termed it interferon (IFN) 5 . Type I IFNs belong to a family of cytokines that attracted much attention owing to their protective role against viral infection. IFNs are widely expressed cytokines that possess strong antiviral and immunomodulatory properties. The IFN family can be classified into three main types of cytokines -type I, type II and type III IFNs. In humans and mice, the type I IFN family is composed of 16 members, namely 12 IFNα subtypes, IFNβ, IFNε, IFNκ and IFNω 6 . By contrast, the type II IFN family includes only one cytokine: IFNγ, which also exhibits antiviral activities. The third type of IFNs is the IFNλ family, which includes IFNλ1 (also known as IL-29), IFNλ2 (also known as IL-28A) and IFNλ3 (also known as IL-28B). On the basis of protein sequence and structure, type III IFNs are markedly different from type I and type II IFNs and are more similar to members of the interleukin-10 (IL-10) family; however, they provoke antiviral responses and induce the activation of IFN-stimulated genes (ISGs) 7 . Recent evidence has uncovered new roles for this family of cytokines beyond their well-known function in viral interference. This article highlights the function of type I IFNs in modulating immune responses. We map the molecular signalling pathways activated by type I IFNs, and describe the function of these cytokines in the response to bacterial ligands and their role in inflammasome activation. In addition, we discuss the role of type I IFNs in intestinal homeostasis and in inflammatory and autoimmune diseases such as coeliac disease, psoriasis, multiple sclerosis and cancer.
Type I IFN production and signalling Induction of type I IFNs by bacterial ligands. Type I IFNs can be produced by almost every cell type, including leukocytes, fibroblasts and endothelial cells. The signalling pathways that lead to the induction of type I IFNs differ depending on the stimulus and the responding cell types, but they ultimately lead to the activation of some common signalling molecules, including TNF receptor-associated factor 3 (TRAF3) 8 and the transcription factors IFN regulatory factor 3 (IRF3) and IRF7. Dimerized IRF3 and IRF7 translocate to the nucleus and, concomitantly with the transcription factor nuclear factor-κB (NF-κB), bind to both the IFNA and IFNB promoters 9 to initiate the transcription of these IFN genes. Although the most important function of type I IFNs is 
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A chronic inflammatory disease of the central nervous system that causes the progressive destruction of the myelin sheaths around axons in any area of the brain, optic nerve and spinal cord. This results in slower nerve impulses.
typically considered to be in the induction of an antiviral immune response, these cytokines are also induced in response to many bacterial pathogens or their products, mainly through Toll-like receptor (TLR)-dependent pathways 10, 11 . TLRs are the key sensors of microbial invasion in mammals 12 , and they activate an innate defence programme that is crucial for host survival. Each TLR senses a particular subset of microbial signature molecules. Most TLRs that recognize bacterial products are linked to the induction of type I IFNs 10 ; these TLRs include TLR3, TLR4, TLR7 and TLR9. Signalling through TLR3 and TLR4 induces type I IFN production in a broad range of cell types in a manner dependent on TIR-domain-containing adaptor protein inducing IFNβ (TRIF). By contrast, TLR7, TLR8 and TLR9 induce type I IFN production in dendritic cells (DCs) -mainly plasmacytoid DCs (pDCs) -via a pathway dependent on myeloid differentiation primary-response protein 88 (MYD88) (TABLE 1) .
However, it became evident that TLR-deficient animals can still produce type I IFNs in response to RNA and DNA ligands 13, 14 . These TLR-independent pathways include the cytoplasmic sensors retinoic-acid-inducible gene I (RIG-I) and melanoma differentiation-associated gene 5 (MDA5). In addition, stimulator of IFN genes (STING) and DNA-dependent activator of IRFs (DAI; also known as DLM1 and ZBP1) have been reported to induce type I IFNs in response to cytosolic DNA 15, 16 . STING is an endoplasmic reticulum-associated protein that has been shown to respond to DNA from various pathogens -including Listeria monocytogenes and the DNA virus herpes simplex virus 1 (HSV-1) -in macrophages, DCs and epithelial cells 15 . DAI, which was the first cytosolic DNA receptor to be described, recognizes viral, bacterial and mammalian double-stranded DNA and induces type I IFN production through the activation of TANK-binding kinase 1 (TBK1), which subsequently phosphorylates IRF3 (REF. 16 ). In addition, DAI stimulates the production of pro-inflammatory cytokines -such as IL-6 and tumour necrosis factor (TNF) -through the activation of the kinase receptorinteracting protein 1 (RIP1), which leads to the phosphorylation of NF-κB inhibitor-α (IκBα) and the subsequent activation of NF-κB 17 . However, DAI-deficient cells can still induce type I IFN production in response to foreign DNA 18 , suggesting the existence of additional mechanisms that contribute to type I IFN production in response to cytosolic DNA. Indeed, a recent study showed that DNA-dependent RNA polymerase III can use cytosolic DNA as a template to synthesize RNA containing a 5ʹ-triphosphate group, and that this RNA activates the RIG-I-IPS1 (IFNB-promoter stimulator 1; also known as MAVS) signalling pathway 19 .
Signalling pathways activated by type I IFNs. Type I IFNs signal through a common heterodimeric receptor, known as the IFNα/β receptor (IFNAR), which is expressed by nearly all cell types. This receptor consists of two subunits -IFNAR1 and IFNAR2 (REF. 20) -that are constitutively associated with Janus kinase 1 (JAK1) and non-receptor tyrosine kinase 2 (TYK2) 21 . Activation of JAK1 and TYK2 results in the tyrosine phosphorylation and activation of several signal transducer and activator of transcription (STAT) family members; in most cells these include STAT1, STAT2, STAT3 and STAT5, but in lymphocytes type I IFNs also activate STAT4 and STAT6 (REFS 22, 23) .
Activation of STAT1 and STAT2 leads to the recruitment of IRF9 and the formation of a STAT1-STAT2-IRF9 complex, which is known as the IFN-stimulated gene factor 3 (ISGF3) complex. This complex then migrates to the nucleus and binds to IFN-stimulated response elements (ISREs) in the promoters of ISGs to initiate gene transcription. Other STAT complexes that do not recruit IRF9, including STAT1 homodimers, bind to IFNγ-activated Figure 1 | Signalling pathways activated by type I and type II IFNs. Different signal transducer and activator of transcription (STAT) family members can be activated by interferons (IFNs). STAT1 homodimers can be formed in response to both type I IFNs and type II IFN (IFNγ). These homodimers bind to IFNγ-activated site (GAS) enhancer elements in the promoters of IFN-stimulated genes, and this results in the induction of genes encoding pro-inflammatory cytokines and apoptotic factors. Type I and type II IFNs can also activate STAT3 homodimers, and this can result in the production of both pro-inflammatory cytokines and anti-inflammatory cytokines (such as interleukin-10 (IL-10)), although the underlying mechanisms are not known. STAT1-STAT2 heterodimers, which are activated by type I IFNs, bind to IFN regulatory factor 9 (IRF9) in the cytosol to form the IFN-stimulated gene factor 3 (ISGF3) complex, which in turn migrates to the nucleus to bind to IFN-stimulated response elements (ISREs) and activate antiviral and antibacterial genes. In addition, type I IFNs stimulate IL-10 production either through the phosphoinositide 3-kinase (PI3K)-AKT pathway or through STAT3 homodimers. Finally, in a STAT-independent manner, type I IFNs activate both p38, which is an upstream activator of several genes regulated by ISREs and GAS elements, and mammalian target of rapamycin (mTOR), which regulates mRNA translation. CREB, cAMP-responsive-element-binding protein; IFNAR, IFNα/β receptor; IFNGR, IFNγ receptor; JAK, Janus kinase; SBE, STAT3-binding element; TBX21, T box 21; TYK2, non-receptor tyrosine kinase 2. site (GAS) enhancer elements in the promoters of ISGs 24, 25 . Both type I and type II IFNs can induce the activation of GAS elements through, for example, the formation of STAT1 homodimers. However, in contrast to type I IFNs, IFNγ cannot induce the formation of ISGF3 complexes and therefore is not able to promote the engagement of ISRE sites to activate those genes that have only ISREs in their promoters 21 (FIG. 1) .
In addition, both type I and type II IFNs can induce the recruitment and phosphorylation of STAT3 (REFS 21, 26) . Following its phosphorylation, STAT3 forms homodimers that translocate to the nucleus, where they bind to STAT3-binding elements (SBEs). STAT1 and STAT3 have a high level of sequence similarity and can heterodimerize and activate similar genes in vitro 27 . However, in vivo, the sets of genes that are activated by these two factors are very different 28 and depend on the cell type and the activating cytokine, and in many physiological contexts STAT1 and STAT3 exert opposing effects. For example, in most cell types, STAT1 activates several proapoptotic and anti-proliferative genes 29, 30 , whereas STAT3 inhibits apoptosis and promotes proliferation through the induction of anti-apoptotic genes of the B cell lymphoma (BCL) family and of oncogenes such as MYC 31, 32 . STAT1 and STAT3 also have opposite roles in inflammation. IFNγ-dependent STAT1 activation usually mediates a pro-inflammatory response that favours the recruitment of immune cells to the site of inflammation 33 , and this increases the production of pro-inflammatory mediators 34 and enhances antigen processing and presentation by MHC class I and II molecules 35, 36 . By contrast, STAT3 is a key mediator of IL-10 signalling, which
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negatively regulates pro-inflammatory responses by activated macrophages and DCs and can directly inhibit STAT1 activation 37 . Interestingly, other receptors, such as the IL-6 receptor, can activate STAT3, but this does not result in an anti-inflammatory response, possibly owing to the participation of additional regulatory factors, such as members of the suppressor of cytokine signalling (SOCS) family 38, 39 . This dual ability of STAT3 to differentially regulate inflammation in different scenarios might explain some of the controversial roles that type I IFNs have in different human conditions (discussed below). Several studies also suggest that cross-regulation between STAT1 and STAT3 and their relative abundance in a cell are the defining factors that determine the biological effects of their upstream activators, such as IL-6 and IFNs 40, 41 . Type I IFNs were also shown to promote the production of IL-10 by lipopolysaccharide (LPS)-stimulated macrophages 42 and by LPS-stimulated human peripheral blood mononuclear cells (PBMCs) 43 . This effect was initially attributed to the activation of STAT3 and IRF1 in IFNα-stimulated human monocytes 44 . However, another study indicated that IFNβ stimulates IL-10 production independently of STAT3, by activating a signalling pathway mediated by JAK1 and phosphoinositide 3-kinase (PI3K). This pathway increases the phosphorylation and nuclear translocation of cAMP-responsiveelement-binding protein (CREB), which promotes IL-10 production in human DCs 45 (FIG. 1) . It is not clear why IL-10 production is mediated by different signalling pathways in response to IFNα (the STAT3 pathway) and IFNβ (the PI3K pathway). However, the differential activation of STAT3 versus STAT1, the ability to induce IL-10 production and/or the participation of additional regulatory elements may explain the diverse effects of type I IFNs in several pathological conditions.
In addition to the JAK-STAT signalling pathways, there is evidence that type I IFNs activate other (non-STAT) signalling pathways that have crucial roles in their different biological properties. For example, it has been shown that type I IFNs activate signalling pathways mediated by mitogen-activated protein kinases (MAPKs), specifically p38 and extracellular signalregulated kinase 1 (ERK1) or ERK2. p38 activity is required for type I IFN-dependent transcription of several genes that are regulated by ISREs and GAS elements in an STAT-independent manner [46] [47] [48] . The functional relevance of this signalling pathway in the biological effects of type I IFNs was evidenced by several studies indicating that p38 is required for the growth-inhibitory and antiviral effects of type I IFNs 49, 50 . In addition to the induction of the p38 signalling cascade, the MAPK/ ERK kinase (MEK)-ERK pathway is activated by type I IFNs 51 and participates in the response to viral infection 52 . Finally, as mentioned above, type I IFNs can also induce the activation of the PI3K signalling pathway in a STAT-independent manner 53, 54 . The PI3K pathway has an important role in mediating gene transcription in response to both type I and type II IFNs and is essential for mediating their antiviral effects against the encephalo myocarditis virus in vitro 55 . Activation of the PI3K signalling cascade controls the activation of mammalian target of rapamycin (mTOR), which regulates mRNA translation. Notably, it was shown that type I IFNs activate pathways for the initiation of mRNA translation that are downstream of mTOR, such as the pathway that involves the activation of p70 S6 kinase and the subsequent phosphorylation of the S6 ribosomal protein 56, 57 . The activation of mTOR by type I IFNs was unrelated to the activation of STAT family members and had no effect on gene transcription 56, 57 , indicating that mTOR selectively regulates IFN-induced mRNA translation. In terms of biological relevance, the activation of mTOR signalling has been shown to mediate the antiviral effects of IFNα against the hepatitis C virus 58 .
Modulating immune responses by type I IFNs
Type I IFNs and suppression of intestinal inflammation. The intestinal microbiota influences the development of local and systemic immune responses and the proliferation and barrier functions of the intestinal epithelium, in part via the activation of host TLRs 59 . Over the last few years, data from our laboratory and others have shown that the systemic administration of TLR9 ligands reduces the severity of colonic injury and inflammation in models of experimental colitis [60] [61] [62] , in part through the TLR9-induced production of type I IFNs by DCs 60 . In addition, IFNα enhances the barrier function of intestinal epithelial cells in vitro by activating STAT3, which maintains the expression of several key tight junction molecules, such as members of the claudin family (J.L., unpublished observations). Similarly, activation of TLR3 by the synthetic viral RNA polyinosinic-polycytidylic acid (polyI:C), which induces type I IFN production in many cell types, was shown to protect mice from experimental colitis 62 . Furthermore, Ifnar -/-mice were extremely susceptible to dextran-sulphate sodium (DSS)-induced colitis 60, 63 , and the administration of recombinant IFNβ to DSS-treated wild-type mice mimicked the anti-inflammatory effects of TLR9 ligands 60 . Different types of haematopoietic cells contribute to DSS-induced colonic inflammation. The depletion of CD11c hi DCs after DSS administration showed that type I IFNs induced by TLR9-activated CD11c hi DCs attenuate the severity of colitis in this model 64 . This study also showed that, depending on their mode of activation, DCs can enhance or inhibit acute DSS-induced colitis by secreting various cytokines (such as TNF, IL-6, IL-10 and type I IFNs), by regulating the production of chemokines that affect the composition of the cellular infiltrate, and by affecting the rate of resolution of inflammation in the colon 64 . In addition, a recent study using a genetically modified strain of Lactobacillus acidophilus that constitutively expresses IFNβ reported that the local expression of IFNAR1 by CD103 + DCs in the Peyer's patches is necessary for protection against DSS-induced intestinal inflammation 63 . In this study, saturating expression of IFNβ before the induction of colitis resulted in the transient suppression of IFNAR1 expression on intestinal CD103 + DCs; this prevented IFNβ from signalling during the inflammatory period, mimicking the phenotype of Ifnar -/-mice with DSS-induced colitis 63 .
Regulation of adaptive immune responses by type I IFNs. In addition to the T cell-independent protective effects of TLR9-mediated type I IFN induction, the role of TLR9 agonist-induced protection in T cell-dependent intestinal inflammation has also been evaluated. TLR9 signalling in DCs in the lamina propria of the small intestine was shown to regulate the functions of regulatory T (T Reg ) cells and effector T cells 65 . In this study, T Reg cell induction was inhibited by DNA derived from commensal bacteria through TLR9, and this was shown to favour the development of protective mucosal immune responses; however the role of type I IFNs in these effects was not clarified 65 . In a T cell-transfer model of colitis, treatment with a TLR9 ligand in the absence of type I IFN signalling failed to induce functionally suppressive CD4 + CD62L
+ T cells, whereas pretreatment of the donor mice with recombinant IFNβ and subsequent T cell transfer resulted in reduced intestinal inflammation and decreased secretion of pro-inflammatory cytokines 66 . Indeed, a role for type I IFNs in TLR9-induced protection in T cell-dependent colitis was previously shown in germ-free mice; in this study, type I IFNs were shown to induce the expression of regulatory markers on CD4 + CD62L + T cells 67 . These data correlate with previous reports that type I IFNs induce regulatory capacities in T cells 68, 69 . Therefore, type I IFNs seem to exert a protective effect in the intestinal mucosa in both acute and chronic models of colitis.
Type I IFNs have been shown to have an important role in the differentiation of both CD4 + and CD8 + T cells. Initial studies found that IL-12 signalling in CD4 + T cells and the subsequent activation of STAT4, which in turn promotes T-bet expression, are crucial events in T helper 1 (T H 1) cell differentiation 70 . In addition to IL-12, type I IFNs were shown to induce the tyrosine phosphorylation and DNA binding of STAT4 (REF. 71) and to act directly on human T cells, but not mouse T cells, to drive T H 1 cell development 72 . However, it was later reported that type I IFNs activate STAT4 directly and that this activation is required for IFNγ production during viral infections in mice 73, 74 . Thus, phosphorylation of STAT4 has been detected in response to type I IFN treatment of both human and mouse T cells [74] [75] [76] but, in contrast with IL-12, type I IFNs were unable to sustain STAT4 phosphorylation and therefore were not sufficient to drive T H 1 cell commitment in vitro 75, 77 . However, type I IFNs regulate T H 1 cell differentiation and effector functions in vivo by synergizing with other cytokines, such as IL-18 and IL-21 (REFS 78-80). Moreover, type I IFNs have been associated with the suppression of T H 2 and T H 17 cell-mediated responses. In human cells, type I IFNs reversed T H 2 cell commitment by suppressing the expression of the T H 2 cell-associated transcription factor GATA-binding protein 3 (GATA3) 78 . Similarly, type I IFNs also suppress the differentiation of T H 17 cells in both mice 81 and humans 82 .
Forkhead box P3 (FOXP3)
+ T Reg cells have a pivotal role in maintaining immunological tolerance and homeostasis. IFNβ treatment markedly improved the frequency and suppressive function of T Reg cells in patients with relapsing-remitting multiple sclerosis 9, 83 and in patients with chronic hepatitis C virus infection 84 , and also increased Foxp3 mRNA expression in PBMCs from patients with relapsing-remitting multiple sclerosis 85 . FOXP3 + T Reg cells show functional and phenotypical plasticity in response to environmental cues and are capable of secreting pro-inflammatory cytokines, for example during severe inflammation 86, 87 . Recently, a higher frequency of IFNγ-secreting T Reg cells has been reported in untreated patients with relapsing-remitting multiple sclerosis compared with the frequency in control individuals 88 . By contrast, in patients treated with IFNβ, the frequency of IFNγ + FOXP3 + T cells was similar to that in healthy controls 88 . In addition, ongoing studies in our laboratory indicate that type I IFN signalling is essential for the maintenance of FOXP3 expression in vivo and for the suppressive activity of T Reg cells in a model of T cellmediated colitis in mice (S. E. Lee, J.M.G.-N. and E.R., unpublished observations). These data suggest a novel role for type I IFNs in T H cell differentiation, as well as in the suppressive function of T Reg cells.
Type I IFNs and inflammasome activation. Four different initiator components that activate different types of inflammasome in response to different stimuli have been identified: NOD-, LRR-and pyrin domaincontaining 1 (NLRP1), NLRP3, NOD-, LRR-and CARD-containing 4 (NLRC4; also known as IPAF) and absent in melanoma 2 (AIM2) 89 . Recently, an inhibitory role for type I IFNs in the activation of the inflammasome has been reported 90 . In this study, type I IFNs inhibited IL-1β production through two different mechanisms. First, IFNβ signalling directly inhibited the NLRP1 and NLRP3 inflammasomes (but not the NLRC4 and AIM2 inflammasomes) in a STAT1-dependent manner. Second, type I IFNs induced the production of IL-10, which in turn activated the transcription factor STAT3 in an autocrine manner to reduce the levels of pro-IL-1α and pro-IL-1β 90 (FIG. 2a) .
Furthermore, type I IFNs increased the susceptibility of mice to Candida albicans infection, an effect that was attributed to the reduction in IL-1β production 90 . Therefore, these data suggested an inhibitory role of type I IFNs in inflammasome activation.
By contrast, previous work reported a positive effect of type I IFNs in inflammasome activation during Francisella tularensis infection 91 . The cytosolic pathogens F. tularensis and L. monocytogenes were both shown to induce a type I IFN response that was essential for caspase 1 activation and IL-1β production. Consistent with this, F. tularensis DNA released into the cytosol activated the production of type I IFNs via IRF3, and this was necessary for the activation of the DNA-sensing AIM2 inflammasome 92 (FIG. 2b) . The discrepancies regarding the role of type I IFN signalling in the production of IL-1β might be related to the type of inflammasome; that is, type I IFNs mediate the inhibition of the NLRP3 inflammasome but the activation of the AIM2 inflammasome. Of particular interest, however, is the case of L. monocytogenes, which has been shown to activate the NLRP3 inflammasome 89 and to increase IL-1β production in an IFNβ-dependent manner. The cytokines IL-1α and IL-1β both bind to IL-1 receptor type 1 (IL-1R1), leading to the activation of NF-κB, MAPKs and certain IRFs 93, 94 . In a recent study, we showed that IL-1R1 is necessary for the TLR9-dependent activation of a type I IFN and IL-10 response 95 . The mechanism by which IL-1R1 signalling modulates type I IFN production involves changes in the ubiquitylation profile of TRAF3, an E3 ubiquitin ligase that interacts with both MYD88 and TRIF, and the type of ubiquitylation determines whether type I IFNs or pro-inflammatory cytokines are produced 8, 96 . Lysine 48 (K48)-linked polyubiquitylation of TRAF3 leads to its proteosomal degradation and the activation of MAPKs and pro-inflammatory cytokines, whereas K63-linked polyubiquitylation of TRAF3 results in the activation of IRFs and subsequent type I IFN production 96, 97 . K63-linked, but not K48-linked, polyubiquitylation of TRAF3 is greatly reduced in the absence of IL-1 signalling. This effect is mediated by deubiquitylating enzyme A (DUBA; also known as OTUD5) 95 , which specifically cleaves the K63-linked polyubiquitin chain on TRAF3 (REF. 97 ). Together, these data suggested a model in which IL-1R1 positively regulates TLR-induced type I IFN production (FIG. 3) . This mechanism may explain previous observations of IL-1R1-mediated protection against intestinal damage from Citrobacter rodentium infection 98 and DSS-induced colitis 98, 99 . Type I IFNs and bacterial infections. Although type I IFNs are induced by bacterial pathogens, the role of type I IFNs in the context of bacterial infections is not completely understood. Bacterial induction of type I IFNs can be mediated through the TLR-dependent recognition of bacterial products, such as LPS, or through the TLR-independent recognition of bacterial ligands that are delivered to the host cytosol. Many investigators have reported a variety of beneficial but also detrimental immune functions for type I IFNs during bacterial infection. For example, type I IFNs have an important role in mediating the pathology of LPSinduced septic shock 84 . By contrast, type I IFNs impair the clearance of L. monocytogenes 100, 101 , Mycobacterium tuberculosis 102 and Chlamydia muridarum 83, 103 , and they are detrimental to host survival after infection with F. tularensis 104 . Two mechanisms have been proposed to explain these phenomena. The first mechanism suggests that microorganisms induce type I IFN production as a strategy to induce apoptosis in lymphocytes, resulting in the suppression of adaptive immune responses 105 . The second mechanism proposes that type I IFNs suppress the production of IL-17A and IL-17F, which are necessary for neutrophil-mediated bacterial clearance 104 . By contrast, type I IFNs are necessary for host resistance against Nature Reviews | Immunology other bacterial pathogens. Mice deficient in IFNAR showed decreased survival and increased bacterial burdens after infection with Streptococcus pneumoniae or Escherichia coli 106 , and this was attributed to the reduced expression of certain cytokines, such as TNF or IFNγ. Moreover, type I IFNs were shown to play an important part in restricting the growth of Legionella pneumophila in macrophages 107 . Taken together, these data show that type I IFNs have a wide range of immunomodulatory effects in response to bacterial infections, and this clearly expands the old notion that type I IFNs serve only as antiviral cytokines.
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Type I IFNs in autoimmune disease
The connection between type I IFNs and several autoimmune and inflammatory disorders is well known, although there is considerable variation in the precise mechanisms and in the role of these cytokines in each condition. Some autoimmune diseases (such as psoriasis and systemic lupus erythematosus (SLE)) are improved by the inhibition of type I IFNs or their upstream regulators. By contrast, other conditions that are characterized by strong T H 1 and/or T H 17 cell responses -such as arthritis, inflammatory bowel disease (IBD) and multiple sclerosis -benefit from the administration of type I IFNs (FIG. 4) . All these inflammatory conditions have an important impact on public health and are the focus of numerous analyses that are readily available in the literature. Therefore, they are only briefly discussed here.
Inflammatory bowel disease. IBD encompasses two major clinical entities: Crohn's disease and ulcerative colitis. Conventional therapies for IBD include 5-aminosalicylic acid (5-ASA), antibiotics (such as ciprofloxacin and metronidazole), corticosteroids, immunosuppressants and TNF-specific antibodies (such as infliximab and adalimumab) 108 . However, poor efficacy in some cases (with 5-ASA or antibiotic treatment) or the development of serious side effects (with corticosteroid treatment) led to the search for other biological therapies. Given their mechanisms of action and their beneficial effects on intestinal homeostasis in animal models, type I IFNs have been tested as a treatment for IBD. Although a few clinical studies of IFNα or IFNβ therapy in patients with ulcerative colitis initially showed promising results [109] [110] [111] , most of these studies failed to demonstrate a beneficial therapeutic effect [112] [113] [114] [115] . Furthermore, documented cases of the exacerbation of ulcerative colitis during IFNα therapy for chronic hepatitis C infection 116, 117 and of the development of ulcerative colitis in patients with multiple sclerosis following treatment with IFNβ1a 118 call into question whether type I IFNs have a therapeutic role in IBD.
Coeliac disease. Coeliac disease has a strong genetic component, as it is highly associated with HLA-DQ2 and HLA-DQ8 alleles 119 . The pathogenesis of coeliac disease involves the polarization of T cells into T H 1 cells and the production of high levels of IFNγ in response to gluten 120 . T H 1 cell polarization is driven by many cytokines, including IL-21, IL-18 and IFNα
121
, the levels of which are usually elevated in the mucosa of untreated patients with coeliac disease 122 . Interestingly, the addition of IFNα-specific, but not IL-18-specific, blocking antibodies to biopsy specimens from patients with coeliac disease inhibits IFNγ production in ex vivo organ cultures 123 . Activation of gluten-specific CD4 + T cells requires that gluten antigens be presented by antigen-presenting cells (APCs) that express HLA-DQ2 or HLA-DQ8 (REFS 124, 125) . The expression of these alleles is relatively low in normal mucosa, but can be upregulated on APCs by type I and type II IFNs, and this facilitates the activation of other inflammatory cells, thereby favouring an inflammatory response to gluten peptides 122, 126, 127 . Notably, enteric viruses can induce the production of type I IFNs, leading to the upregulation of HLA-DQ2 or HLA-DQ8 on APCs, and this would result in the perfect milieu for the activation of gluten-specific T H 1 cells. The development of coeliac disease in patients undergoing treatment with recombinant type I IFNs, such as patients with hepatitis C virus infection 122, 128 , also supports this hypothesis. Psoriasis. Psoriasis is a T cell-mediated chronic inflammatory skin disease that is characterized by the production of large amounts of type I IFNs by pDCs that are recruited to and accumulate in the dermis. High levels of type I IFNs are responsible for the local activation and expansion of pathogenic T cell populations, which in turn trigger the abnormal proliferation and differentiation of keratinocytes and the development of diffuse epidermal hyperplasia, known as acanthosis. The activation of T H 17 cells has been associated with this phenomenon 129 , and the blockade of type I IFN signalling by IFNAR-specific antibodies effectively inhibited the activation of autoreactive T cells and the development of skin lesions in a xenograft model of psoriasis 130 . In addition, antibodies specific for blood DC antigen 2 (BDCA2; also known as CLEC4C) suppressed the production of type I IFNs by pDCs through the activation of SRC family protein tyrosine kinases, and this also inhibited the activation of autoreactive T cells and the development of skin lesions 131 .
Systemic lupus erythematosus. The activation of pDCs by nucleic acid-containing immune complexes leads to the production of large amounts of type I IFNs, and elevated levels of IFNα are detected in the blood of patients with SLE 132, 133 . Type I IFNs in the serum of patients with SLE were responsible for the differentiation of monocytes into DCs and the expression of MHC class II molecules and the co-stimulatory molecules CD80 and CD86 by these DCs. In addition, normal monocytes cultured with serum from patients with SLE, but not those cultured with autologous serum, could present self antigens to autoreactive T cells 134 . In another study, type I IFNs produced by pDCs, together with IL-6, were also shown to induce plasma cell differentiation 135 .
Patients with SLE are treated with various medications, including non-steroidal anti-inflammatory drugs, gluco corticoids and immunosuppressants. Many of these therapies are associated with severe adverse effects. Therefore, there is a medical need for more-specific and safer therapies that target selective pathways involved in the pathogenesis of SLE. Recent data from a Phase I clinical trial showed that the administration of neutralizing antibodies specific for IFNα effectively inhibited the overexpression of IFNα-inducible genes in skin lesions of patients with SLE 136 .
Multiple sclerosis. It is generally considered that both T H 1 and T H 17 cells are involved in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis (EAE; an animal model of multiple sclerosis). Human recombinant IFNβ therapy is widely prescribed for certain stages of multiple sclerosis, particularly relapsing-remitting multiple sclerosis 137 . Two human recombinant IFNβ forms are currently used: IFNβ1a, which is produced in Chinese hamster ovary cells; and IFNβ1b, which is produced in E. coli 138 . The exact mechanism behind the beneficial effect of type I IFNs in multiple sclerosis and EAE is not known, but recombinant IFNβ reduces the attack frequency and severity of multiple sclerosis 138, 139 . However, not all patients with relapsing-remitting multiple sclerosis respond to treatment, and the development of IFNβ-specific autoantibodies may cause relapses and side effects.
IFNβ-deficient mice are more susceptible to EAE development 140 , and type I IFNs can attenuate EAE in mice 141 , suggesting that IFNβ modulates both multiple sclerosis and EAE. In addition, the conditional deletion of Ifnar1 showed that specific myeloid cells, such as monocytes and macrophages 142 or DCs 143 , modulate autoimmune inflammation of the central nervous system in an IFNAR-dependent manner. The expression of IFNAR by microglial cells (brain-endogenous macrophages) also modulates the severity of EAE 142 . IFNβ reduces the ability of microglial cells to present antigens, and this in turn reduces the recruitment and effector functions of encephalitogenic T cells 144 . Another mechanism that was proposed to explain the immunomodulatory effects of IFNβ in patients with multiple sclerosis involves the induction of IL-10. Indeed, upregulation of IL-10 production is a hallmark of IFNβ treatment in patients with multiple sclerosis 145 .
Cancer. Type I IFNs have been extensively used for the treatment of several types of cancer, including haematological malignancies (for example, hairy cell leukaemia and some B or T cell lymphomas) and solid tumours (for example, melanoma, renal cell carcinoma and Kaposi's sarcoma) 146, 147 . IFNα1-producing tumour cells were shown to be less tumorigenic and less able to metastasize when transferred into mice, and this was attributed to the activation of several host antitumour mechanisms at the tumour site 148 . These studies suggested that type I IFNs could act as an adjuvant in cancer vaccines 133 .
Indeed, IFNα showed an effective adjuvant activity in patients with melanoma 149 . In addition to their putative role as adjuvants in antitumour vaccines, type I IFNs inhibit angio genesis and act on DCs to enhance the ability of these cells to cross-present apoptotic antigens to CD8 + T cells 150 to trigger a cytotoxic T lymphocyte response 151, 152 .
The main pitfall for the use of type I IFNs as an antitumour therapy is the frequent severe side effects, which decrease the enthusiasm for the application of type I IFNs in this clinical setting.
Concluding remarks
Our understanding of the functions of type I IFNs and the mechanisms that control these functions is continuously evolving. Since their discovery, type I IFNs have been associated with host defence responses to viral infections, and it is only recently that their functions in bacterial infections and in immune-mediated and inflammatory disorders have been appreciated. The molecular mechanisms by which type I IFNs exert their immunomodulatory functions and the reasons why they restrain the development of some immunopathologies while increasing the severity of others are still largely unknown. One possible explanation for these opposing effects could be found in the differential regulation of STAT family members in different tissues or organs under different physiological and/or inflammatory conditions. A better understanding of the underlying pathophysiology is mandatory for the design of effective treatments with type I IFNs or with type I IFN-specific neutralizing antibodies.
